Get informed when a big investor buys or sells
+ FollowOvervalued by 2467.9% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $11,001.00 |
|---|---|
| Enterprise Value | $-12,156,135.00 |
| Earnings per Share | $-16.38 |
| Beta | 0.15 |
| Outstanding Shares | 1,037,874 |
| P/E Ratio | -1.05 |
|---|---|
| PEG | 2.91 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -123.16 |
| Enterprise Value to EBIT | 1.64 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 67.58%▼ 584.10% |
|---|---|
| Total Invested | $9,611▼ 93.39% |
| Investors Holding | 7▼ 21.00% |
Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge resear...